OTTAWA, May 29, 2024 (GLOBE NEWSWIRE) -- The federal budget, which is set to be passed before the end of June, includes changes to the Food & Drugs Act that gives the Health Minister the power (Section 326) to override regulatory approval for over-the-counter drugs, natural health products, and medical devices. The Consumer Choice Center's Toronto based David Clement explained why this new power sets Canada down a dangerous path.

"Giving the Health Minister the power to override Health Canada approvals on OTC drugs, NHPs, and medical devices creates a scenario that is ripe for ministerial abuse, with a health minister sidestepping Health Canada to regulate from a position of bias, or in response to bad headlines," said Clement.

"This power is even more problematic given the products and drugs that are covered by the change. As written, a future Health Minister could use this power to restrict access to OTC drugs like Plan B, or contraception like IUDs, and do so entirely at their discretion," said Clement.

"If the Liberals are truly committed to ensuring that women have access to certain forms of contraception, they wouldn't be giving a future Health Minister the authority and ability to override Health Canada approvals. By giving future Health Ministers this power they are setting the table for restrictions," said Clement.

***CCC North American Affairs Manager David Clement is available to speak with accredited media on consumer regulations and consumer choice issues. Please send media inquiries to david@consumerchoicecenter.org.***

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org.

CONTACT:

David Clement

Consumer Choice Center

david@consumerchoicecenter.org

905-220-0704

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Ban on puberty blockers to be made indefinite on experts’ advice

New services for patients under record pharmacy funding deal

New protections for whistleblowers under NHS manager proposals

CMA wins drug market sharing appeal

NTC gives long term consistency to its ophtha portfolio with another MDR CE Certificate approval

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

New research highlights that privacy, reassurance and education are essential for Pharmacy First to be adopted by people in England

Polpharma Group Calls for Urgent Action to Protect early equitable access to medicines for European patients